Bernard Klein

Q: What Schools Are Affiliated With Bernard Klein

Bernard Klein is affiliated with the following schools: Aarhus University, University of Montpellier

Bernard Klein's AcademicInfluence.com Rankings

Bernard Klein

Philosophy

#7220

World Rank

#10401

Historical Rank

Logic

#4284

World Rank

#5555

Historical Rank

philosophy Degrees

Bernard Klein

Biology

#9800

World Rank

#13048

Historical Rank

Molecular Biology

#1367

World Rank

#1394

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Bernard Klein's Degrees

PhD Molecular Biology University of California, Berkeley
Doctorate Medicine Stanford University

Why Is Bernard Klein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bernard Klein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. (1989) (838)
Interleukin-6 in human multiple myeloma. (1995) (568)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. (2004) (534)
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. (2003) (508)
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. (1989) (489)
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. (1991) (425)
A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1 (1996) (378)
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma (1997) (372)
A Meta‐Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web‐Based Expression Atlas (2007) (355)
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. (1994) (338)
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma (2007) (320)
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. (1992) (310)
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. (1994) (306)
The human cumulus--oocyte complex gene-expression profile. (2006) (284)
Interleukin-6 as a Therapeutic Target (2015) (283)
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. (1989) (282)
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. (1995) (270)
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. (2005) (261)
Human peripheral blood B‐cell compartments: A crossroad in B‐cell traffic (2010) (253)
Embryonic stem cell markers expression in cancers. (2009) (239)
An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. (2009) (227)
Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells (2010) (227)
Survival and Proliferation Factors of Normal and Malignant Plasma Cells (2003) (224)
CD200 is a new prognostic factor in multiple myeloma. (2006) (220)
Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy (1993) (210)
Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. (2003) (207)
Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. (1998) (187)
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma (2011) (187)
JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells (2000) (176)
Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. (2011) (173)
Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. (1990) (172)
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. (2001) (170)
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays (2002) (166)
C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. (1992) (163)
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. (2002) (163)
p53 and RAS gene mutations in multiple myeloma. (1992) (162)
Cytokine network in human multiple myeloma. (1992) (158)
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells (2003) (155)
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. (2009) (154)
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines (2011) (149)
Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. (1998) (148)
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. (2006) (144)
The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells (1998) (140)
A gene expression signature shared by human mature oocytes and embryonic stem cells (2009) (138)
Induction of angiogenesis by normal and malignant plasma cells. (2009) (138)
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1 (2000) (137)
Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation (2011) (132)
Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. (1994) (130)
Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication. (1991) (127)
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. (1990) (126)
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. (1995) (120)
C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. (1998) (119)
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. (1996) (118)
Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. (1995) (116)
Mechanisms of bone lesions in multiple myeloma. (1992) (111)
Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis1 (2007) (111)
IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors (2014) (111)
Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B‐cell malignancies (1993) (110)
Mutations of the p53 gene in human myeloma cell lines. (1992) (109)
Hyaluronic Acid Induces Survival and Proliferation of Human Myeloma Cells through an Interleukin-6-mediated Pathway Involving the Phosphorylation of Retinoblastoma Protein* (2001) (107)
Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. (1995) (106)
Insulin‐like growth factor induces the survival and proliferation of myeloma cells through an interleukin‐6‐independent transduction pathway (2000) (105)
APRIL and TACI interact with syndecan‐1 on the surface of multiple myeloma cells to form an essential survival loop (2009) (104)
CD200: a putative therapeutic target in cancer. (2008) (104)
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments] (1990) (103)
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells (2005) (102)
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma (2006) (101)
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. (1995) (101)
Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. (1999) (101)
IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. (1991) (101)
High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo (1992) (100)
Cytokine-binding proteins: stimulating antagonists. (1995) (100)
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. (2008) (99)
Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. (1996) (98)
In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma (1991) (97)
GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells (2015) (93)
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. (2012) (90)
Myeloproliferative virus, a cloned murine sarcoma virus with spleen focus-forming properties in adult mice (1980) (90)
Interleukin‐6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti‐gp130 monoclonal antibodies (1995) (88)
Interleukin‐6 dependence of advanced malignant plasma cell dyscrasias (1992) (87)
Anti‐tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside (2013) (86)
The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. (1999) (85)
Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production (1998) (80)
Dendritic cell-based vaccine: a promising approach for cancer immunotherapy (1999) (80)
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. (2008) (80)
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. (2004) (79)
SULFs in human neoplasia: implication as progression and prognosis factors (2011) (78)
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis (2009) (77)
MMSET is overexpressed in cancers: link with tumor aggressiveness. (2009) (77)
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study (2009) (76)
Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. (2000) (75)
Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells (2002) (75)
Cytokine gene expression in human multiple myeloma (1993) (74)
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors (2000) (72)
gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro (1993) (72)
In vitro expansion of gamma delta T cells with anti‐myeloma cell activity by Phosphostim and IL‐2 in patients with multiple myeloma (2007) (70)
Microarray‐based understanding of normal and malignant plasma cells (2006) (68)
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. (2006) (67)
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation (2010) (67)
Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. (1998) (67)
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays (2010) (66)
APRIL is overexpressed in cancer: link with tumor progression (2009) (66)
Clinical and prognostic role of annexin A2 in multiple myeloma. (2012) (66)
STEAP1 is overexpressed in cancers: a promising therapeutic target. (2012) (65)
Gene expression of anti‐ and pro‐apoptotic proteins in malignant and normal plasma cells (2009) (65)
A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. (1998) (64)
Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. (1999) (64)
Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells (2009) (64)
EZH2 in normal hematopoiesis and hematological malignancies (2015) (64)
IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. (1998) (63)
γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody (2011) (63)
Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. (2011) (62)
Targeting NF‐κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth (2007) (61)
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects (2005) (60)
Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro (2000) (60)
Major role of the soluble interleukin‐6/interleukin‐6 receptor complex for the proliferation of interleukin‐6‐dependent human myeloma cell lines (1997) (58)
Phenotypic analysis of human myeloma cell lines (1989) (55)
Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data (2010) (55)
The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma (1992) (54)
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma (2017) (54)
Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin‐6 signal transducer gp130 1 (1997) (54)
Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum. (1999) (54)
Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma (2016) (53)
A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments (2008) (52)
Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. (1988) (52)
DNA repair pathways in human multiple myeloma (2013) (52)
Modeling risk stratification in human cancer (2013) (49)
TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. (2007) (49)
Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. (1997) (48)
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors (2013) (48)
Study of a virus-induced myeloproliferative syndrome associated with tumor formation in mice. (1980) (48)
miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression (2015) (47)
Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors (2012) (47)
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. (1990) (46)
Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies. (1991) (44)
Embryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective. (2013) (44)
Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine (2011) (43)
Evidence against KSHV infection in the pathogenesis of multiple myeloma. (1998) (42)
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma (2012) (42)
Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor1 (2006) (42)
Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. (1999) (41)
Human anti‐mouse antibody response to the injection of murine monoclonal antibodies against IL‐6 (1994) (41)
Serum interleukin 10 in early stage multiple myeloma (1992) (41)
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy (2014) (41)
Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL2 production by human lymphocytes treated with Bestatin. (1984) (40)
Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy (2001) (40)
Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. (2011) (40)
No detectable malignant B cells in the peripheral blood of patients with multiple myeloma (1989) (40)
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance (2019) (39)
Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma (2011) (39)
Spontaneous secretion of tumor necrosis factor‐beta by human myeloma cell lines (1989) (39)
Interleukin-10 and Gp130 cytokines in human multiple myeloma. (1999) (38)
The CD24 antigen discriminates between pre-B and B cells in human bone marrow. (1990) (38)
Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. (1990) (37)
Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. (1996) (37)
Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells. (1983) (37)
Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma (2014) (36)
Increased Plasma-Immune Cytokines throughout the High-Dose Melphalan-Induced Lymphodepletion in Patients with Multiple Myeloma: A Window for Adoptive Immunotherapy (2009) (36)
An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. (1995) (35)
Malignant plasma cell lines express a functional CD28 molecule (1998) (35)
An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. (1999) (34)
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. (2013) (33)
gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. (1993) (33)
Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell (2017) (33)
Inhibiting IL-6 in human multiple myeloma. (1992) (32)
Hairy cell transformation of a B-cell chronic lymphocytic leukemia: a morphological, cytochemical, phenotypic and molecular study. (1991) (32)
Large scale and clinical grade purification of syndecan-1+ malignant plasma cells. (1997) (32)
Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24 (2009) (32)
The Bcl‐2 family member Bfl‐1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti‐apoptotic factor for myeloma cells (2004) (31)
Interleukin 6 production by cardiac myxomas may explain constitutional symptoms. (1992) (31)
Interleukin‐10 induces interleukin‐11 responsiveness in human myeloma cell lines (1995) (30)
Production of growth factors by human myeloma cells. (1987) (29)
Effects of myeloproliferative sarcoma virus on the pluripotential stem cell and granulocyte precursor cell populations of DBA/2 mice. (1981) (29)
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. (2012) (28)
Controlled Epstein–Barr virus reactivation after allogeneic transplantation is associated with improved survival (2014) (28)
Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma (2013) (28)
Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. (2005) (28)
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells (2015) (28)
Studies of bone and soft‐tissue tumours induced in rats with radioactive cerium chloride (1977) (27)
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications (2007) (26)
Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells (2013) (26)
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells (2018) (26)
ETV6 mutations and loss in AML-M0 (2008) (26)
B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. (2007) (25)
A Phase I/II Study of TACI-Ig To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma or Active Previously-Treated Waldenström’s Macroglobulinemia. (2005) (25)
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells (2019) (24)
Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb. (1998) (24)
Drug metabolism and clearance system in tumor cells of patients with multiple myeloma (2014) (24)
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients (2012) (24)
In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. (2000) (23)
Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma (2010) (23)
Total fertilization failure and molecular abnormalities in metaphase II oocytes. (2008) (23)
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma (2015) (23)
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma (2014) (23)
Gene expression-based risk score in diffuse large B-cell lymphoma (2012) (23)
Immunoassay for functional human soluble interleukin-6 receptor in plasma based on ligand/receptor interactions. (1994) (22)
Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. (2006) (22)
Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment. (2011) (22)
Analysis of the myeloproliferative sarcoma virus genome: limited changes in the prototype lead to altered target cell specificity (1981) (22)
A highly sensitive quantitative bioassay for human interleukin-11. (1994) (22)
A study of added GM-CSF independent granulocyte and macrophage precursors in mouse spleen infected with myeloproliferative sarcoma virus (MPSV). (1982) (22)
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1 (2014) (22)
Kaposi's sarcoma-associated herpesvirus is not detected with immunosuppression in multiple myeloma. (1998) (22)
The role of interleukin 1 and interleukin 2 in human T colony formation. (1983) (21)
Phenotypic analysis of human myeloma cell lines. (1989) (21)
Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor. (1997) (21)
Both human alpha/beta and gamma interferons upregulate the expression of CD48 cell surface molecules. (1997) (21)
CLONAL REARRANGEMENT OF IMMUNOGLOBULIN GENES IN THE PERIPHERAL BLOOD OF MULTIPLE MYELOMA PATIENTS (1989) (20)
Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma (2012) (20)
Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients (2014) (20)
DNA methylation score is predictive of myeloma cell sensitivity to 5‐azacitidine (2014) (20)
Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies. (1994) (19)
CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma (2017) (19)
Letter to the editor: The bone‐resorbing activity of interleukin‐6 (1991) (19)
Early events in human B cell activation: metabolic pathways vary according to the first signal used (1986) (18)
Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. (1993) (18)
Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies. (1994) (18)
Differential effects of lenalidomide during plasma cell differentiation (2016) (18)
STUDY OF CELL DEATH IN FRIEND LEUKAEMIA (1976) (18)
Human autologous rosettes. IV. Their relation with interleukin 2 activity production and natural killer cells in cancer patients. (1984) (17)
Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma1 (2009) (17)
Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients (2006) (17)
γδ T Lymphocytes Count Is Normal and Expandable in Peripheral Blood of Patients with Follicular Lymphoma, Whereas It Is Decreased in Tumor Lymph Nodes Compared with Inflammatory Lymph Nodes (2009) (17)
Comparison of murine leukemia virus, human immunodeficiency virus, and adeno-associated virus vectors for gene transfer in multiple myeloma: lentiviral vectors demonstrate a striking capacity to transduce low-proliferating primary tumor cells. (2003) (17)
Molecular analysis of the IL‐6 receptor in human multiple myeloma, an IL‐6‐related disease (1994) (16)
Interleukin 2 production in B cell chronic lymphocytic leukemia. (1985) (16)
Update of gp130 cytokines in multiple myeloma (1998) (16)
RECQ helicases are deregulated in hematological malignancies in association with a prognostic value (2016) (16)
Characterization of human FCRL4-positive B cells (2017) (16)
MYEOV is a prognostic factor in multiple myeloma. (2010) (16)
Positioning NK-kappaB in multiple myeloma. (2010) (15)
ETV 6 mutations and loss in AML-M 0 (2008) (15)
The Glycome of Normal and Malignant Plasma Cells (2013) (15)
Up‐regulation of interleukin (IL)‐6 receptor gene expression in vitro and in vivo in IL‐6 deprived myeloma cells (1992) (14)
Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma (2015) (13)
Human natural killer cells suppress the proliferation of B cells. (1990) (13)
A ciliary neurotrophic factor-sensitive human myeloma cell line. (1996) (13)
Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro. (1991) (13)
Mobilization of plasma cells in healthy individuals treated with granulocyte colony‐stimulating factor for haematopoietic stem cell collection (2011) (13)
Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6. (1999) (13)
Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model (2001) (12)
Myeloproliferative sarcoma virus: Its effects on erythropoiesis in adult DBA/2J mice (1983) (12)
No expansion of the pre-B and B-cell compartments in the bone marrow of patients with multiple myeloma. (1991) (12)
Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma (2007) (12)
Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma (2013) (12)
Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage (2016) (12)
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? (2012) (12)
BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone (2003) (11)
Rituximab Activity Is Potentiated by GM-CSF in Patients with Relapsed, Follicular Lymphoma: Results of a Phase II Study. (2005) (11)
Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? (1993) (11)
DNA repair in diffuse large B‐cell lymphoma: a molecular portrait (2015) (11)
Production of interleukin 2 in multiple myeloma. (1986) (11)
Immunomodulating IL-6 activity by murine monoclonal antibodies. (1995) (11)
Hypoxia favors the generation of human plasma cells (2017) (10)
MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma. (1998) (10)
Functional interaction of the gp80 and gp130 IL-6 receptors in human B cell malignancies. (1998) (10)
Clinical applications of IL6 inhibitors. (1992) (10)
Molecular Classification of Multiple Myeloma (MM) Based on Gene Expression Profiling (GEP) and Fluorescence In Situ Hybridisation (FISH) Is an Independent Predictor for Event Free Survival (EFS). (2005) (10)
Identification of HLA‐A2 restricted T‐cell epitopes within the conserved region of the immunoglobulin G heavy‐chain in patients with multiple myeloma (2008) (9)
Limiting dilution cloning of B cells from patients with multiple myeloma: Emergence of non‐malignant B‐cell lines (1989) (9)
Human T-lymphocyte colonies: generation of colonies in different lymphocyte subpopulations. (1981) (9)
Myeloproliferative Sarcoma Virus stimulates pluripotent hematopoietic stem cells and provokes tumoral transformation of the hematopoietic microenvironment in vitro. (1983) (9)
Effects of an anti-interleuktn-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia (1993) (9)
Expression Map of the Human Exome in CD34+ Cells and Blood Cells: Increased Alternative Splicing in Cell Motility and Immune Response Genes (2010) (9)
Myeloproliferative syndrome induced by MPSV in DBA/2 mice: presence of a mixed-colonies promoting activity (MPA) in the spleen. (1983) (9)
Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins (2012) (9)
Concanavalin A-induced interferon gamma production by murine spleen cells and T cell lines. Lack of correlation with Lyt 1,2 phenotype. (1984) (8)
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification. (2011) (8)
Nature and mechanisms of action of co-operating cells controlling human T-colony formation. (1982) (8)
Activation molecules on human myeloma cells. (1999) (8)
BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma (2018) (8)
Myeloproliferative sarcoma virus (MPSV), a new tool for the study of hematopoiesis. (1981) (8)
Friend leukemia: a model for the physiopathology of human chronic leukemia. (1975) (8)
Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL‐6 receptors (2001) (8)
Thymosin β4 in multiple myeloma: friend or foe (2010) (8)
Identification of a novel antigenic structure of the human receptor for interleukin‐6 involved in the interaction with the glycoprotein 130 chain (1996) (8)
Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry (2018) (8)
Regulation of interleukin-2 production in rheumatoid arthritis. (1987) (7)
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm (2010) (7)
A New Molecular Classification of Multiple Myeloma Using Gene Expression Profiling and Fluorescence In Situ Hybridisation as Predictor for Event Free Survival. (2004) (7)
CD 200 : a putative therapeutic target in cancer (2017) (7)
[Advances in the biology of multiple myeloma]. (1990) (7)
Induction of Human T Colony Formation by Phorbol Myristate Acetate (1983) (6)
Analysis of the B-cell compartment in plasma cell leukemia and multiple myeloma: immunoglobulin gene rearrangement of EBV-infected B-cell lines. (1993) (6)
[Oocyte and embryo quality: do the apoptotic markers have a place in the preimplantation genetic diagnostic?]. (2008) (6)
Control of human T-colony formation by interleukin-2. (1985) (6)
The bone-resorbing activity of interleukin-6. (1991) (6)
[An experimental model of osteosarcomas in rats ]. (1982) (6)
Hematopoietic precursors in disease induced by the myeloproliferative sarcoma virus. (1983) (6)
Physiopathology of human and virus-induced murine leukemias. (1976) (6)
Interleukin 2 production in bone marrow of normal individuals and patients associated with B‐cell chronic lymphocytic leukaemia (1988) (6)
Abnormal behavior of protein kinase C in the human myeloma cell line, RPMI 8226 (1990) (6)
A Phase I/II Study of Atacicept (TACI-Ig) To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma (MM) or Active Previously Treated Waldenstrom’s Macroglobulinemia (WM). (2006) (6)
Studies on erythroid-committed precursor cells in the polycythaemic mouse. (1977) (6)
Interrelationship between autoimmunity and B-lymphoid cell oncogenesis in humans. (1989) (5)
Role of interleukin-6 in multiple myeloma. (1992) (5)
Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acute-phase proteins? [letter; comment] (1991) (5)
Induction in rats of paranasal sinus carcinomas with radioactive cerium chloride. (1977) (5)
The role of interleukin-2 in T colony formation by human pre-T cells (pTCFC). (1984) (5)
Antibody specificity of the human monoclonal immunoglobulins: the elusive target antigen. (1989) (5)
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma. (2013) (5)
The receptor super-antagonist Sant7. (1997) (5)
Cellular proliferation in the spleen of DBA/2 mice infected with a myeloproliferative sarcoma virus(MPSV). (1981) (4)
Inhibition of SUV39H Methyltransferase As a Potent Therapeutic Target in Multiple Myeloma (2015) (4)
The relationship between autoimmune states and B cell proliferations. (1989) (4)
Immunophenotypic Analysis of Myeloma Precursors: Antigens for Therapeutic Targeting (2010) (4)
Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity. (1997) (4)
CD5 B lymphocyte antigen in monoclonal gammopathy (1992) (4)
CD5 positive B lymphocytes: a link between autoimmunity and B-cell oncogenesis. (1988) (4)
Asymptomatic Multiple Myeloma - Background of Progression, Evolution, and Prognosis (2016) (4)
Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features (2020) (3)
Production of B‐cell growth factor interleukin 2 and gamma interferon by peripheral blood lymphocytes from patients with chronic lymphocytic leukemia of B‐cell type (1988) (3)
Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance. (1992) (3)
Low dose of deoxyguanosine increases IL-2 receptors of IL-2-dependent cultured T cells. (1984) (3)
Studies of the immunoglobulin eluted from the glomeruli of mice chronically infected with lymphocytic choriomeningitis virus. (1977) (3)
IL-6 SUPPORTS THE GENERATION OF HUMAN LONG-LIVED PLASMA CELLS 1 IN COMBINATION WITH EITHER APRIL OR STROMAL CELL SOLUBLE (2015) (3)
Modulation of PHA-induced T colony formation by phorbol myristic acetate. (1983) (3)
Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance [letter; comment] (1992) (3)
Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. (2022) (3)
The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors (2004) (3)
Gene Expression Profiling and Real-Time PCR Analyses Make It Possible To Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma. (2007) (2)
Interferons in the treatment of multiple myeloma. (1990) (2)
Recent advantages in the biology of IL-6 in multiple myeloma (1991) (2)
[Could apoptotic markers help the exploration of male infertility?]. (2008) (2)
[Relative study of soluble syndecan-1 and prognosis of patients with multiple myeloma]. (2001) (2)
Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acute-phase proteins? (1991) (2)
Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial (2013) (2)
No preferential use of the VH(V) family in human multiple myeloma (1989) (2)
GP130 cytokines, interferon, survival and proliferation of human myeloma cells. (1997) (2)
Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications (2011) (2)
Suppressor effect of prostaglandins on T colony formation. (1983) (2)
Characterization of Mesenchymal Stem Cells Abnormalities in Multiple Myeloma. (2006) (2)
A Novel Class of Sulfonanilides Entering Clinical Trials for Targeted Treatment of Multiple Myeloma: Dual-Mechanism Compounds Inhibiting HIF1A-Signaling and Inducing Apoptosis (2010) (2)
Inhibition of HIF1A Signaling by a Novel Class of Sulfonanilides for Targeted Treatment of Multiple Myeloma. (2009) (2)
Amplification of the polyclonal activation of human T cells. I. Null-cell products promote the polyclonal proliferation of T cells. (1982) (2)
Rearrangement of CCNDl ( BCLI / PRADI ) 3 ’ Untranslated Region in Mantle-Cell Lymphomas and t ( llql 3 )-Associated Leukemias (2002) (1)
Osteoclast Gene Expression Profiling in Multiple Myeloma (2008) (1)
Angiogenesis in Multiple Myeloma (MM): Angiogenic Switch or Reflexion of Plasma Cell Number? A Gene Expression Based Survey in Primary Myeloma Cells and the Bone Marrow Microenvironment. (2006) (1)
[Growth factors in multiple myeloma]. (1990) (1)
EXAMINATION OF KSHV INFECTION IN MULTIPLE MYELOMA PATIENTS (1998) (1)
Inhibition of Multiple Myeloma Cells Growth by AS602868, a Pharmacological Inhibitor of IKK2. (2006) (1)
Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines (2009) (1)
Carcinoembryonic-Antigen-Related Cell Adhesion Molecule (CEACAM) Expression on Multiple Myelomas Inhibits Their Recognition by Autologous Memory CD8 T Cells (2008) (1)
Tocilizumab in Treatment for Patients With COVID-19. (2021) (1)
Correction to: Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features (2020) (1)
Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease (2012) (1)
[Cytokines and lymphoplasmocytic proliferations: essential role of interleukin 6]. (1993) (1)
Major immunoglobulin capping deficiency in the peripheral blood B cells of patients with Sjögren's syndrome. (1992) (1)
Syndecan-1 Is Essential for the Myeloma Cell Growth Factor Activity of EGF-Family Ligands in Multiple Myeloma. (2005) (1)
for personalized and risk adapted treatment in multiple myeloma (2010) (1)
A Small Molecule That Selectively Targets BLM Helicase Has a Therapeutic Interest in Multiple Myeloma (2016) (1)
Mononuclear cells release low molecular weight factors with anti-cancer activity: A lower level of production by cells of cancer patients. (1998) (1)
Transcriptome of Human Cumulus-Oocyte Complex: DNA Microarray Approach (2005) (1)
Clonal and Subclonal Cytogenetic Aberrations: Association with D-Type Cyclin Expression and Event-Free Survival (EFS) in Multiple Myeloma (MM). (2006) (1)
Efficient Vaccination of Follicular Lymphoma (FL) Patients with Multiple Intradermal (ID) and Intravenous (IV) Administrations of Mature Dendritic Cells (DC) Loaded with Tumor Cell Lysate Ex Vivo. (2005) (1)
Human T lymphocyte colonies. I. Surface markers and cytotoxic potential of colony cells. (1981) (1)
A Gene Expression Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma. (2008) (1)
TACI and BCMA, Unlike BAFF-R, Are Expressed by Human Myeloma Cell Lines and TACI+ Cell Lines Have a Gene Signature Indicative of Mature Bone Marrow Plasma Cells and Bone Marrow Environment Dependence. (2005) (1)
IFN-α Is a Survival Factor for Human Myeloma Cells and Reduces Dexamethasone-Induced Apoptosis (1998) (1)
Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma (2020) (1)
Clinical and prognostic role of annexin A 2 in multiple myeloma (2012) (1)
Malignant Plasma Cells Responsible for Multiple Myeloma Relapse Are Detectable and Survive Nine Days After High Dose Melphalan: Highlight of An Optimal Therapeutic Window ? (2011) (1)
Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6. (2012) (1)
Mobilization of Plasma Cells in Healthy Individuals Treated with G-CSF for Hematopoietic Stem Collection. (2009) (1)
Multiple Myeloma: Global Expression Profiling (GEP) Indicates Upregulation of the Ribosomal Machinery in Hyperdiploid Clones. (2004) (1)
Delay and not deficiency in cap formation of peripheral blood B cells in patients with multiple myeloma (1988) (1)
Binding of TACI and APRIL to Syndecan-1 Confer on Them a Major Role in Multiple Myeloma. (2007) (1)
powerful myeloma staging system C-reactive protein and beta-2 microglobulin produce a simple and (2013) (0)
Cellular proliferation kinetics of the murine sarcoma induced by the Moloney sarcoma virus (1982) (0)
Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop (2010) (0)
Etiology of Paget's disease of bone: A new perspective (1992) (0)
Study of the cell proliferation kinetics in mpsv-infection dba/2 mice. Abstr. (1979) (0)
1101 Human Tumor Cells Inhibit T Cell Responses Through Expression of Carcinoembryonic-antigen-related Cell Adhesion Molecule-6 (CEACAM-6) (2012) (0)
Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Vaccination Strategies Determined by Microarray Analysis. (2006) (0)
B033 Aurora-Kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma (2009) (0)
Cell composition containing macrophages having antiinfective properties and hematopoietic, and a process for their preparation. (2000) (0)
Cytokine Pathways in Myeloma Growth and Survival (2009) (0)
Interleukin-l0 Is a Proliferation Factor But Not a Differentiation Factor for Human Myeloma Cells (2002) (0)
Identification of a Gene Signature Associated to Treatment Response to Palbociclib in Multiple Myeloma (2016) (0)
Role of RECQ1 helicase in multiple myeloma drug resistance (2015) (0)
The Human Plasma Cell Gene Expression Program. (2004) (0)
Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity (2021) (0)
B552 The European Myeloma Stem Cell Network (MSCNET) (2009) (0)
Identification of a novel antigenic domain of the human receptor for IL-6 involved in its interaction with the gp130 chain (1996) (0)
P43. ErbB-signalling in multiple myeloma – From the identification as potential therapeutic target by gene expression analysis and functional testing to clinical trials (2006) (0)
O-172: Human cumulus cells gene expression profile according to ovarian hyperstimulation protocols (hMG vs. recFSH) (2006) (0)
Autoimmune conditions induced by epithelial solid tumors (2004) (0)
RECQ helicases are deregulated in hematological malignancies in association with a prognostic value (2016) (0)
[An attempt at identification of osteoclastic activation factors implicated in myeloma]. (1988) (0)
Myeloma Are Not Infected With Kaposi's Sarcoma-Associated Herpesvirus Clinical-Grade Functional Dendritic Cells From Patients With Multiple (2013) (0)
Tumoral Sample Peripheral blood Pleural effusion Peripheral blood Pleural effusion Peripheral blood Peripheral blood Peripheral blood Peripheral blood Peripheral blood Bone marrow and the percentages of myeloma cells (2002) (0)
Derivation and characterization of the first abnormal human embryonic stem cell carrying a mutated von Hippel Lindau allele (2008) (0)
CD200 Is a Potent New Growth Factor in Multiple Myeloma through IGF-1R Interaction (2017) (0)
Role Of RECQ1 Helicase In Multiple Myeloma Biology and Drug Resistance (2013) (0)
Asymptomatic Multiple Myeloma – Molecular Background of Progression and Prognosis (2017) (0)
On the Redox Profile of B- Cell Terminal Differentiation and Multiple Myeloma: New Insights and Therapeutic Opportunities (2016) (0)
Myeloma of T Cells from Patients with Multiple Activity and Decreases CD45RA Expression Lenalidomide Enhances Antigen-Specific (2011) (0)
of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. (2014) (0)
Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling. (2007) (0)
Ribosomal Proteins Are Overexpressed in Hyperdiploid Multiple Myeloma. (2007) (0)
Unsupervised Analysis of Gene Expression Profile of 37 Human Myeloma Cell Lines Identifies 5 Classes of HMCL Characterized by a Set of 213 Genes Related to Molecular Classification of Patients with Multiple Myeloma (2008) (0)
Immunophenotypic Analysis of Myeloma Precursors (2010) (0)
Umbilical cord blood transplantation in relapsed multiple myeloma (2011) (0)
Controlled Epstein-Barr Virus Reactivation After Allogenic Transplantation Improves Survival and Is Associated To An Expansion Of Natural Killer Cells (NK) (2013) (0)
Multiple Myeloma A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human (2013) (0)
Interest of FDG-PET Scanning for the Monitoring of Immunotherapies for Follicular Lymphoma. (2006) (0)
Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma (2013) (0)
This information is current as Granulocyte Colony-Stimulating Factor High-Dose Cyclophosphamide and in Stem Cell Autografts by Mobilization with Functional Regulatory T Cells Are Collected (2017) (0)
[The expression, secretion and regulation of membrane-soluble syndecan-1 in human multiple myeloma cells]. (2000) (0)
Inhibition of H3K9 methyltransferase as a potent therapeutic target in multiple myeloma (2015) (0)
Production of interleukin 6 by atrial myxomas may explain systemic symptoms (1991) (0)
Regulatory and Activated T Cells in Stem Cell Autografts Collected by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor. (2005) (0)
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells (2018) (0)
Bone Morphogenic Protein 6: A Prognostic Factor Expressed by Normal Plasma Cells and Multiple Myeloma Cells Inhibiting Their Proliferation and Angiogenesis Induction (2008) (0)
Mathematical Assessment of Prognosis (2013) (0)
Cytotoxic T Cells Results in Tumor-Specific Recognition by Cells Following Retroviral Gene Transfer Induced Expression of B 7-1 on Myeloma (1999) (0)
Human B Cell to Plasma Cell Differentiation Preplasmablast Population in the Process of Characterization of a Transitional (2011) (0)
Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma 1 (2009) (0)
Interleukine 6 production may explain constitutional symptoms of cardiac myxomas (1990) (0)
Decreased Thymosin Beta 4 Expression Results in Poor Prognosis and Decreased Survival in Multiple Myeloma (2008) (0)
The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma (2014) (0)
Evaluation of a novel class of sulfonanilides for targeted treatment of multiple myeloma: Dual-mechanism compounds inhibiting HIF1 alpha-signaling and inducing apoptosis (2011) (0)
A167 BMP6: A Novel Antiangiogenic, Antiproliferative, and Prognostic Factor Expressed by Myeloma Cells (2009) (0)
Short And Long Term Effects In Human Cells As A Consequence Of High LET Irradiation (2001) (0)
Kinetic model of Friend virus-induced leukemia. (1975) (0)
[Immunology of myeloma]. (1987) (0)
Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features (2020) (0)
Patterns of Microrna in Plasma Cells: From Normal Differentiation to Multiple Myeloma (2016) (0)
Abstract 2669: Autologous Bone Marrow Mononucleated Cell Infusion for Acute Myocardial Infarction in Patients with Severe Left Ventricular Dysfunction: Results of the BONAMI Trial (A Mutlicenter Randomized Controlled Trial) (2008) (0)
Metascoring and Gene Expression Profiling in Clinical Routine in Multiple Myeloma (2011) (0)
Cancer-Testis Antigens in Multiple Myeloma PCR Analyses Identify Novel Potential Gene Expression Profiling and Real-Time (2009) (0)
Kinetic Model of Friend Virus-Induced Leukemia1 (1976) (0)
P21. A molecular classification of multiple myeloma (MM) based on gene expression profiling and fluorescence in situ hybridisation as independent prognostic factor for event free survival (EFS) (2006) (0)
Input of DNAMicroarrays to Identify Novel Mechanisms in Multiple Myeloma Biology andTherapeutic Applications (2007) (0)
Amplification ofthepolyclonal activation ofhumanT cells (1982) (0)
Phenotype and Cytokines Production by Human Myeloma Cell Lines (1988) (0)
A New Method for Predictor Calculation Based on Signed-Rank Call Algorithms. Application to Microarray Gene Expression Analysis of Human Multiple Myeloma. (2004) (0)
Determined by Microarray Analysis Expression Patterns and Prognosis Value Cancer/Testis Genes in Multiple Myeloma: (2007) (0)
Action of actinomycin d on mpsv-induced neoplasia. Abstr. (1981) (0)
molecule-6 cells through carcinoembryonic antigen-related cell adhesion Tumor cells in multiple myeloma patients inhibit myeloma-reactive (2013) (0)
with plasma cell leukemia Murine anti-interleukin-6 monoclonal antibody therapy for a patient (2011) (0)
Umbilical Cord Blood Transplantion In Relapsed Multiple Myeloma (2010) (0)
New anti-protein mediators therapeutic kits, method of preparation and pharmaceutical compositions containing them. (1993) (0)
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling (2022) (0)
Pertubations induced by pv-msv virus in adult mice. Abstr. (1977) (0)
Major role of the soluble IL-6R (sCD126) for the proliferation of an IL-6-dependent myeloma cell line (1996) (0)
Cytokines in Multiple Myeloma (2004) (0)
Specific inhibition of IL-6 signaling with monoclonal antibodies directed against the gp130 receptor (1996) (0)
B310 Molecular Classification of Myeloma Cell Lines Is Related to that of Patients with Myeloma (2009) (0)
chemokines promoting myeloma cell migration Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 (2011) (0)
PLASMA CELL LABELING INDEX, BETA 2-MICROGLOBULIN, AND C-REACTIVE PROTEIN :WHATH IS THE BEST COMBINATION FOR MYELOME PROGNOSIS ? AUTHORS' RESPONSE (1993) (0)
Comparison of Immune Reconstitution after Umbilical Cord Blood (UCB) and Allogenic Peripheral Blood Stem Cell (APBSC) Transplantation in Patients with Advanced Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML). (2007) (0)
Abstract 124: Involvement of the notch pathway in the clonogenicity of human multiple myeloma cell lines (2010) (0)
Microenvironment and Immunology Bioactivity and Prognostic Signi fi cance of Growth Differentiation Factor GDF 15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma (2012) (0)
prognostic relevance of the expression of its receptor The role of IGF-1 as a major growth factor for myeloma cell lines and the (2009) (0)
for Adoptive Immunotherapy Patients with Multiple Myeloma: A Window Melphalan-Induced Lymphodepletion in throughout the High-Dose Increased Plasma-Immune Cytokines (2009) (0)
130409 BAI REVIEW CGT- HAL VERSION (2013) (0)
Amphiregulin Is Produced by Myeloma Cells and Is Involved in Tumor-Environment Interactions in Multiple Myeloma. (2004) (0)
B577 Osteoclast Gene Expression Profiling in Multiple Myeloma (2009) (0)
Interterleukin-6 (IL-6) Produced by Monocyte Activation Reduces Dendritic Cell (DC) Differentiation in Patients with Multiple Myeloma (MM) and Malignant Lymphoma (ML): Role of CNTO 328, an Anti-IL-6 Monoclonal Antibody (Mab) and Possible Clinical Applications. (2004) (0)
A Clinically Usable Gene Expression Report for Risk Assessment and Identification of Possible Therapeutic Targets in Multiple Myeloma. (2009) (0)
Biological and Clinical Responses after Intradermal and Intravenous Administrations of Mature Dendritic Cells Loaded with Tumor Lysate in Follicular Lymphoma Patients. (2006) (0)
TUMOR NECROSIS FACTOR IS A SURVIVAL AND PROLIFERATION FACTOR FOR HUMAN MYELOMA CELLS1 (2007) (0)
B050 Angiogenesis in Multiple Myeloma: Induction by Normal Plasma Cell — and Aberrantly Expressed Genes (2009) (0)
Immunosuppression in Multiple Myeloma Kaposi's Sarcoma-Associated Herpesvirus Is Not Detected With (2013) (0)
[Human plasmacytoma from biology to clinical practice]. (1993) (0)
B553 In Silico Analysis of Global Gene Expression in Myeloma CCL: In Search of Stem Cell Genes (2009) (0)
[Solid tumors which induce autoimmune conditions]. (1988) (0)
Prognostication by miRNome-Profiling in Multiple Myeloma (2011) (0)
University of Groningen Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138(-) and CD138(+) plasma cells Caraux, (2010) (0)
Conserved natural humoral immunity to thyroglobulin in patients with multiple myeloma (1992) (0)
Monoclonal antibodies define different functional epitopes on gp 130 receptor tranducers (1994) (0)
B034 A Gene Expression—Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bernard Klein?

Bernard Klein is affiliated with the following schools:

Bernard Klein's Academic­Influence.com Rankings

Bernard Klein's Degrees

Why Is Bernard Klein Influential?

Bernard Klein's Published Works

Published Works

What Schools Are Affiliated With Bernard Klein?

Bernard Klein's AcademicInfluence.com Rankings